Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Coupling Between Conformational Dynamics and Catalytic Function at the Active Site of the Lead-Dependent Ribozyme.

White NA, Sumita M, Marquez VE, Hoogstraten CG.

RNA. 2018 Aug 15. pii: rna.067579.118. doi: 10.1261/rna.067579.118. [Epub ahead of print]

PMID:
30111534
2.

Enzyme-Driven Chemo-and Radiation-Therapy with 12 Pyrimidine Nucleoside Analogs Not Yet in the Clinic.

Greer S, Han T, Dieguez C, McLean N, Saer R, Reis I, Levi J, Marquez VE.

Anticancer Agents Med Chem. 2017;17(2):250-264.

PMID:
27745548
3.

Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.

Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A.

Epigenetics. 2016 Mar 3;11(3):184-93. doi: 10.1080/15592294.2016.1146851. Epub 2016 Feb 18.

4.

MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.

Vella S, Pomella S, Leoncini PP, Colletti M, Conti B, Marquez VE, Strillacci A, Roma J, Gallego S, Milano GM, Capogrossi MC, Bertaina A, Ciarapica R, Rota R.

Clin Epigenetics. 2015 Aug 6;7:82. doi: 10.1186/s13148-015-0107-z. eCollection 2015.

5.

Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs.

Fulkerson CM, Dhawan D, Jones DR, Marquez VE, Jones PA, Wang Z, Wu Q, Klaunig JE, Fourez LM, Bonney PL, Knapp DW.

Vet Comp Oncol. 2017 Mar;15(1):226-236. doi: 10.1111/vco.12159. Epub 2015 Jul 14.

PMID:
26178438
6.

Selective Phosphorylation of South and North-Cytidine and Adenosine Methanocarba-Nucleosides by Human Nucleoside and Nucleotide Kinases Correlates with Their Growth Inhibitory Effects on Cultured Cells.

Sjuvarsson E, Marquez VE, Eriksson S.

Nucleosides Nucleotides Nucleic Acids. 2015;34(8):544-64. doi: 10.1080/15257770.2015.1031248.

PMID:
26167664
7.

Chemical biology of nucleic acids.

Barciszewski J, Marquez VE, Vasseur JJ, Markiewicz WT.

ACS Chem Biol. 2015 Jun 19;10(6):1358-61. doi: 10.1021/acschembio.5b00320. No abstract available.

PMID:
26087829
8.

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.

Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK, Kim CF.

Nature. 2015 Apr 9;520(7546):239-42. doi: 10.1038/nature14122. Epub 2015 Jan 28.

9.

Toxicity of Bacillus thuringiensis var. israelensis in aqueous suspension on the South American common frog Leptodactylus latrans (Anura: Leptodactylidae) tadpoles.

Lajmanovich RC, Junges CM, Cabagna-Zenklusen MC, Attademo AM, Peltzer PM, Maglianese M, Márquez VE, Beccaria AJ.

Environ Res. 2015 Jan;136:205-12. doi: 10.1016/j.envres.2014.10.022. Epub 2014 Nov 20.

PMID:
25460638
10.

Redox metabolism in Trypanosoma cruzi. Biochemical characterization of dithiol glutaredoxin dependent cellular pathways.

Márquez VE, Arias DG, Chiribao ML, Faral-Tello P, Robello C, Iglesias AA, Guerrero SA.

Biochimie. 2014 Nov;106:56-67. doi: 10.1016/j.biochi.2014.07.027. Epub 2014 Aug 7.

PMID:
25110158
11.

Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.

Garcia LC, Donadío LG, Mann E, Kolusheva S, Kedei N, Lewin NE, Hill CS, Kelsey JS, Yang J, Esch TE, Santos M, Peach ML, Kelley JA, Blumberg PM, Jelinek R, Marquez VE, Comin MJ.

Bioorg Med Chem. 2014 Jun 15;22(12):3123-40. doi: 10.1016/j.bmc.2014.04.024. Epub 2014 Apr 20.

12.

Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.

Pu Y, Kang JH, Sigano DM, Peach ML, Lewin NE, Marquez VE, Blumberg PM.

J Med Chem. 2014 May 8;57(9):3835-44. doi: 10.1021/jm500165n. Epub 2014 Apr 17.

13.

Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.

Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, Kurokawa M.

Cancer Sci. 2014 May;105(5):512-9. doi: 10.1111/cas.12386. Epub 2014 Mar 30.

14.

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.

Ciarapica R, Carcarino E, Adesso L, De Salvo M, Bracaglia G, Leoncini PP, Dall'agnese A, Verginelli F, Milano GM, Boldrini R, Inserra A, Stifani S, Screpanti I, Marquez VE, Valente S, Mai A, Puri PL, Locatelli F, Palacios D, Rota R.

BMC Cancer. 2014 Feb 27;14:139. doi: 10.1186/1471-2407-14-139.

15.

EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD.

Vella S, Gnani D, Crudele A, Ceccarelli S, De Stefanis C, Gaspari S, Nobili V, Locatelli F, Marquez VE, Rota R, Alisi A.

Int J Mol Sci. 2013 Dec 12;14(12):24154-68. doi: 10.3390/ijms141224154.

16.

Lysine methylation promotes VEGFR-2 activation and angiogenesis.

Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello CE, Rahimi N.

Sci Signal. 2013 Dec 3;6(304):ra104. doi: 10.1126/scisignal.2004289.

17.

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).

Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'Agnese A, Walters ZS, Verginelli F, De Sio L, Boldrini R, Inserra A, Bisogno G, Rosolen A, Alaggio R, Ferrari A, Collini P, Locatelli M, Stifani S, Screpanti I, Rutella S, Yu Q, Marquez VE, Shipley J, Valente S, Mai A, Miele L, Puri PL, Locatelli F, Palacios D, Rota R.

Oncogene. 2014 Aug 7;33(32):4173-84. doi: 10.1038/onc.2013.471. Epub 2013 Nov 11.

PMID:
24213577
18.

Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64. doi: 10.1128/AAC.01703-13. Epub 2013 Oct 7.

19.

PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.

Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, Yamanaka R, Tanaka Y, Nukiwa T, Marquez VE, Ishikawa Y, Ichinose M, Aburatani H.

Sci Rep. 2013;3:1911. doi: 10.1038/srep01911.

20.

Redox metabolism in Trypanosoma cruzi: functional characterization of tryparedoxins revisited.

Arias DG, Marquez VE, Chiribao ML, Gadelha FR, Robello C, Iglesias AA, Guerrero SA.

Free Radic Biol Med. 2013 Oct;63:65-77. doi: 10.1016/j.freeradbiomed.2013.04.036. Epub 2013 May 8.

PMID:
23665397
21.

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J.

Leukemia. 2013 Dec;27(12):2341-50. doi: 10.1038/leu.2013.94. Epub 2013 Mar 29.

22.

Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.

Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y.

Gastroenterology. 2013 May;144(5):1086-1097.e9. doi: 10.1053/j.gastro.2013.01.058. Epub 2013 Feb 7.

PMID:
23395645
23.

Synthesis of a North-methanocarba-thymidine (N-MCT) analog.

Thompson A, Marquez VE.

Curr Protoc Nucleic Acid Chem. 2012 Dec;Chapter 1:Unit1.29. doi: 10.1002/0471142700.nc0129s51.

PMID:
23255201
24.

MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD).

Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, Marquez VE, Zhang Q, Norris DA, Shellman YG.

J Invest Dermatol. 2013 May;133(5):1286-93. doi: 10.1038/jid.2012.400. Epub 2012 Nov 29.

25.

Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.

Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R.

Neuro Oncol. 2013 Feb;15(2):149-60. doi: 10.1093/neuonc/nos285. Epub 2012 Nov 28.

26.

N-methyl-substituted fluorescent DAG-indololactone isomers exhibit dramatic differences in membrane interactions and biological activity.

Gal N, Kolusheva S, Kedei N, Telek A, Naeem TA, Lewin NE, Lim L, Mannan P, Garfield SH, El Kazzouli S, Sigano DM, Marquez VE, Blumberg PM, Jelinek R.

Chembiochem. 2011 Oct 17;12(15):2331-40.

27.

Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer.

Ren SX, Cheng AS, To KF, Tong JH, Li MS, Shen J, Wong CC, Zhang L, Chan RL, Wang XJ, Ng SS, Chiu LC, Marquez VE, Gallo RL, Chan FK, Yu J, Sung JJ, Wu WK, Cho CH.

Cancer Res. 2012 Dec 15;72(24):6512-23. doi: 10.1158/0008-5472.CAN-12-2359. Epub 2012 Oct 24. Erratum in: Cancer Res. 2015 Sep 1;75(17):3684. Shen, Jin [corrected to Shen, Jing].

28.

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J.

Cancer Cell. 2012 Oct 16;22(4):506-523. doi: 10.1016/j.ccr.2012.09.003.

29.

Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.

Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M.

PLoS One. 2012;7(10):e47663. doi: 10.1371/journal.pone.0047663. Epub 2012 Oct 15.

30.

Differential furanose selection in the active sites of archaeal DNA polymerases probed by fixed-conformation nucleotide analogues.

Ketkar A, Zafar MK, Banerjee S, Marquez VE, Egli M, Eoff RL.

Biochemistry. 2012 Nov 13;51(45):9234-44. doi: 10.1021/bi301043k. Epub 2012 Oct 30.

31.

Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K.

Clin Cancer Res. 2012 Nov 15;18(22):6227-38. doi: 10.1158/1078-0432.CCR-12-0873. Epub 2012 Aug 29.

32.

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H.

Lung Cancer. 2012 Nov;78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003. Epub 2012 Aug 25.

33.

Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis.

Krämer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P, Gelse K, Beyer C, Distler A, Marquez VE, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2013 Apr;72(4):614-20. doi: 10.1136/annrheumdis-2012-201615. Epub 2012 Aug 21.

PMID:
22915621
34.

The effect on quadruplex stability of North-nucleoside derivatives in the loops of the thrombin-binding aptamer.

Aviñó A, Mazzini S, Ferreira R, Gargallo R, Marquez VE, Eritja R.

Bioorg Med Chem. 2012 Jul 15;20(14):4186-93. doi: 10.1016/j.bmc.2012.06.005. Epub 2012 Jun 9.

35.

A nucleotide-analogue-induced gain of function corrects the error-prone nature of human DNA polymerase iota.

Ketkar A, Zafar MK, Banerjee S, Marquez VE, Egli M, Eoff RL.

J Am Chem Soc. 2012 Jun 27;134(25):10698-705. doi: 10.1021/ja304176q. Epub 2012 Jun 14.

36.

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E.

Mol Cancer Ther. 2012 Aug;11(8):1735-46. doi: 10.1158/1535-7163.MCT-12-0037. Epub 2012 May 23.

37.

Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification.

Svedlund J, Koskinen Edblom S, Marquez VE, Åkerström G, Björklund P, Westin G.

J Clin Endocrinol Metab. 2012 Jul;97(7):E1307-15. doi: 10.1210/jc.2011-3136. Epub 2012 Apr 27.

PMID:
22544915
38.

Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.

Momparler RL, Idaghdour Y, Marquez VE, Momparler LF.

Leuk Res. 2012 Aug;36(8):1049-54. doi: 10.1016/j.leukres.2012.03.001. Epub 2012 Apr 1.

39.

The conformationally constrained N-methanocarba-dT analogue adopts an unexpected C4'-exo sugar pucker in the structure of a DNA hairpin.

Pallan PS, Marquez VE, Egli M.

Biochemistry. 2012 Apr 3;51(13):2639-41. doi: 10.1021/bi300215k. Epub 2012 Mar 20.

40.

Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester.

Geczy T, Peach ML, El Kazzouli S, Sigano DM, Kang JH, Valle CJ, Selezneva J, Woo W, Kedei N, Lewin NE, Garfield SH, Lim L, Mannan P, Marquez VE, Blumberg PM.

J Biol Chem. 2012 Apr 13;287(16):13137-58. doi: 10.1074/jbc.M111.320010. Epub 2012 Feb 18.

41.

Targeting the enhancer of zeste homologue 2 in medulloblastoma.

Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA, Dubuc A, Taylor MD, Foreman NK, Vibhakar R.

Int J Cancer. 2012 Oct 15;131(8):1800-9. doi: 10.1002/ijc.27455. Epub 2012 Jul 30.

42.

PRC2 directly methylates GATA4 and represses its transcriptional activity.

He A, Shen X, Ma Q, Cao J, von Gise A, Zhou P, Wang G, Marquez VE, Orkin SH, Pu WT.

Genes Dev. 2012 Jan 1;26(1):37-42. doi: 10.1101/gad.173930.111.

43.

DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M.

Mol Cancer Ther. 2012 Feb;11(2):370-82. doi: 10.1158/1535-7163.MCT-11-0458. Epub 2011 Dec 27.

44.

Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.

He S, Wang J, Kato K, Xie F, Varambally S, Mineishi S, Kuick R, Mochizuki K, Liu Y, Nieves E, Mani RS, Chinnaiyan AM, Marquez VE, Zhang Y.

Blood. 2012 Feb 2;119(5):1274-82. doi: 10.1182/blood-2011-06-364422. Epub 2011 Nov 23.

45.

Polycomb genes and cancer: time for clinical application?

Crea F, Paolicchi E, Marquez VE, Danesi R.

Crit Rev Oncol Hematol. 2012 Aug;83(2):184-93. doi: 10.1016/j.critrevonc.2011.10.007. Epub 2011 Nov 22. Review.

PMID:
22112692
46.

EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K, Thiele CJ.

Cancer Res. 2012 Jan 1;72(1):315-24. doi: 10.1158/0008-5472.CAN-11-0961. Epub 2011 Nov 8.

47.

Derivation of new human embryonic stem cell lines reveals rapid epigenetic progression in vitro that can be prevented by chemical modification of chromatin.

Diaz Perez SV, Kim R, Li Z, Marquez VE, Patel S, Plath K, Clark AT.

Hum Mol Genet. 2012 Feb 15;21(4):751-64. doi: 10.1093/hmg/ddr506. Epub 2011 Nov 4.

48.

Influence of sugar ring conformation on the transportability of nucleosides by human nucleoside transporters.

Damaraju VL, Mowles D, Smith KM, Yao SY, Young JD, Marquez VE, Cass CE.

Chembiochem. 2011 Dec 16;12(18):2774-8. doi: 10.1002/cbic.201100567. Epub 2011 Nov 4.

PMID:
22052809
49.

Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors.

Wierda RJ, Kuipers HF, van Eggermond MC, Benard A, van Leeuwen JC, Carluccio S, Geutskens SB, Jukema JW, Marquez VE, Quax PH, van den Elsen PJ.

J Cell Mol Med. 2012 Aug;16(8):1866-77. doi: 10.1111/j.1582-4934.2011.01482.x.

50.

Polycomb repressor complex-2 is a novel target for mesothelioma therapy.

Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, Zhu YJ, Ripley RT, Mathur A, Liu F, Yang M, Meltzer PA, Marquez VE, De Rienzo A, Bueno R, Schrump DS.

Clin Cancer Res. 2012 Jan 1;18(1):77-90. doi: 10.1158/1078-0432.CCR-11-0962. Epub 2011 Oct 25.

Supplemental Content

Loading ...
Support Center